Specialty R&D
Our Specialty Pharma business delivers innovative medicines focused on meeting important medical needs across therapeutic categories, including central nervous system disorders (Parkinson’s Disease, Spasticity, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.
We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.
Clinical Activities
Summary of Specialty R&D Graphic
LYVISPAH™ (Spasticity, MS & other spinal cord disorders) Est Launch 2022
DHE Autoinjector (Migraine and Cluster Headache) Est Launch 2022
IPX203 (Parkinson’s Disease) Est Launch 2023
K127 (Myasthenia Gravis) Est Launch 2023-2024
K114 (Hypothyroidism) Est Launch 2024-2025
K128 (Sialorrhea / Movement Disorders) Est Launch 2025-2026
*Orphan Disease
*As of January 2022
